In humans, there are few reports dealing with cytokine production in chronic GVHD.
in patients with cGVHD than in those without cGVHD. Thus, pathogenesis of cGVHD in mice and in humans MNCs to 899 ؎ 61 pg/10 6 MNCs. Thus, low IL-10 production may cause high IFN-␥ release. In anti-CD3-actimight be distinct, and production of IL-10 in patients with cGVHD might be decreased, as has recently been shown vated MNCs obtained from patients with cGVHD IFN-␥ production was significantly increased (324- 3331 for patients with acute GVHD. 8 However, so far, production of IL-10 ex vivo has not been determined in patients pg/10 6 MNC; 1849 pg/10 6 MNC) compared to healthy donors (127-900 pg/10 6 MNC; 305 pg/10 6 MNC P Ͻ with cGVHD. In this study we compared the production of IL-10 in patients with or without cGVHD as well as healthy 0.01). In addition, median IFN-␥ release by anti-CD3-activated MNCs obtained from patients without controls and correlated it with IFN-␥ production. cGVHD (464 pg/10 6 MNC) was about five-fold lower than in patients with cGVHD. In contrast to cytokine production, the differential leukocyte count Methods and patients (percentages of monocytes, T cells and CD4/CD8 ratio) was essentially the same both in patients with or without Patients cGVHD. Thus, a different activation of Th-1 and Th-2 cells by anti-CD3 may be responsible for the deviant Ten patients aged 9-56 years receiving bone marrow transplantation for AML, ALL, CML, NHL and MDS were cytokine productions in patients with cGVHD. In conclusion, we observed significantly decreased IL-10 prostudied between 6 months and 5 years after transplant. Patients were matched for time after transplant, and extent duction in patients with cGVHD and an increased median IFN-␥ secretion, which may contribute to the of HLA-match (Table 1 ). Four out of five patients with chronic GVHD received cyclosporin A (CsA), while none altered cytokine production after allogeneic BMT leading to cGVHD. Thus, supplementing IL-10 may become of the five patients without GVHD were treated with immunosuppressive agents. GVHD was evaluated by skin a new strategy for preventing cGVHD. Keywords: graft-versus-host disease; bone marrow transbiopsy in all patients. consent prior to inclusion into the study. 
Reagents Results
Reagents used were anti-CD3 (Ortho Diagnostics, HeidelBasal IL-10 production by MNCs obtained from patients berg, Germany), cytokine ELISA and anti-IL-10 (Biowith or without cGVHD as well as from healthy donors Source, Camarillo, CA, USA).
was very low, and no significant differences between these three groups were found ( Figure 1 ). However, after stimulation with anti-CD3, ex vivo IL-10 production significantly Isolation and stimulation of MNC increased in patients and volunteers ( Figure 1 ; P Ͻ 0.01).
MNCs of patients and 10 healthy volunteers were isolated
In patients with cGVHD IL-10 production by anti-CD3 from heparinized blood samples by Ficoll density centrifugstimulated MNCs (median/range of anti-CD3-stimulated ation and viability was assessed by trypan blue staining to MNCs: 400/26-650 pg/10 6 MNCs) was significantly be above 95% in all patients and volunteers. Cell concenreduced compared to healthy donors (3054/679-6361 trations were adjusted to 10 6 /ml MNCs and stimulated with pg/10 6 MNCs; P Ͻ 0.01) or patients without cGVHD an anti-CD3 monoclonal antibody (100 ng OKT3/10 6 (1314/646-2662 pg/10 6 MNCs, Figure 1 ; P Ͻ 0.05). MNCs) on ice for 30 min. After activation, cells were resusBasal IFN-␥ production in patients and healthy volunpended in RPMI 1640 supplemented with 10% heat-inactiteers was very low and no significant differences were vated fetal calf serum and penicillin/streptomycin at a found ( Figure 2 ). After stimulation with anti-CD3 ex vivo density of 10 6 /ml for 24 h. Cell-free supernatants were har-IFN-␥ production by MNCs obtained from patients vested and stored at −70°C until cytokines were deterwith/without cGVHD and healthy volunteers was signifimined.
cantly raised compared with basal levels (Figure 2 ; P Ͻ 0.01). In patients with cGVHD, anti-CD3-stimulated IFN-␥ release (median/range: 1849/334-3331 pg/10 6 MNCs) was Cytokine ELISA significantly increased compared with healthy volunteers (305/127-900 pg/10 6 MNCs; P Ͻ 0.05; Figure 2 ). In IL-10 and IFN-␥ were detected by commercially available addition, median IFN-␥ release by MNCs of patients with-ELISA (BioSource) as has been described previously. 9 out cGVHD (464 pg/10 6 MNCs) was about five-fold lower than in patients with cGVHD. However, IFN-␥ secretion FACS analysis from MNCs of patients without cGVHD ranged from 110 to 3695 pg/10 6 MNCs.
Percentages of CD3-, CD4-and CD8-positive T cells as
To investigate whether changes in cellular subset compowell as CD14-positive monocytes were assessed by FACS sition of MNCs might account for cytokine differences analysis of MNCs using FITC-labelled mouse monoclonal between patients with or without cGVHD, percentage of T antibodies (Becton Dickinson, Heidelberg, Germany). Anticells and monocytes within the MNC fractions as well as bodies were dissolved in 0.2 m phosphate-buffered saline CD4/CD8 ratios were compared. The percentage of T cells pH 7 containing 0.1% BSA and 0.1% sodium azide. MNCs or monocytes obtained from patients with cGVHD were no were labelled with these antibodies or mouse antibodies of different from those of patients without cGVHD (Table 2 ). identical isotypes (as controls). After 30 min on ice, cells However, relative numbers of T cells obtained from both were washed three times and fluorescence intensity was patient groups were significantly reduced compared with determined by FACS scan (Becton Dickinson).
healthy donors (Table 2 ; P Ͻ 0.01). In contrast, the relative number of monocytes in patients after BMT was significantly increased compared with healthy donors (Table 2 ; P Statistical analysis Ͻ 0.01). Thus, although cellular subsets of MNCs differed between patients and controls, these differences seem not The Wilcoxon test was used for statistical analysis of the data.
to account for changes of cytokine production observed in and VI) were cultured with medium or anti-CD3. After 24 h cell-free supernatants were harvested and assayed for IL-10 by a specific ELISA. with cGVHD (0.33) were significantly lower than in healthy volunteers (1.6; Table 2 ; P Ͻ 0.01). However, there was no obvious difference between patients with or without using the anti-IL-10 antibody (Figure 3 ; P Ͻ 0.01). Thus, a low IL-10 production could account for an increased GVHD (in patients without GVHD median CD4/CD8 ratio was 0.3).
release of IFN-␥ by anti-CD3-activated MNCs. To investigate whether a low IL-10 production could be responsible for the observed increase of IFN-␥ release in patients with cGVHD, we stimulated MNCs from healthy Discussion donors with anti-CD3 in the presence or absence of an anti-IL-10 antibody. We used a concentration of the anti-IL- 10 The pathogenesis of cGVHD is not well understood. Mice with cGVHD showed an increased production of Th-2 cytoantibody which had been shown to inhibit detection of IL-10 from supernatants of anti-CD3-stimulated MNCs by kines like IL-4, IL-6 and IL-10, autoimmune phenomena and increased serum Ig levels. [3] [4] [5] [6] Application of IL-12, more than 80% (data not shown). The anti-CD3-stimulated IFN-␥ production increased from 354 Ϯ 134 pg/10 6 MNCs which inhibits Th-2 activation and supports Th-1 activation, induced an acute GVHD in mice that would otherwise without the anti-IL-10 MoAb to 899 Ϯ 61 pg/10 6 MNCs of IFN-␥ synthesis and they could partially overcome the suppressive effects of IL-10.
17,18
To investigate mechanisms of the decreased IL-10 production in patients with cGVHD, the subset compositions of MNCs were analyzed. However, neither an increased percentage of monocytes in patients without cGVHD compared to patients with cGVHD nor significant changes in CD4 to CD8 ratios between these patients were observed. Thus, changes of relative numbers of T cells and monocytes as well as the CD4/CD8 ratios could not explain cytokine abnormalities found in patients with cGVHD. However, altered activation and expansion of Th-1 or Th-2 cells by anti-CD3 stimulation might be responsible for the differences observed.
The use of CsA in vitro reduced IL-10 production by anti-CD3-activated MNCs, but it also inhibited production of IFN-␥ (data not shown). In a recent report we demon- the time of ex vivo investigation. 8 Thus, immunosuppressive treatment might not explain the significant decrease of IL-10 production by MNCs from patients with cGVHD develop cGVHD. 10 Thus, chronic GVHD in mice seems to be related to increased activation of Th-2 cells. A key regucompared with patients without cGVHD. Therefore, different ratios of Th-1 and Th-2 cells obtained after anti-CD3 lator of autoantibody production and autoimmune phenomena might be the increased production of IL-10 by Th-2 stimulation rather than toxic effects of CsA on cytokine production seem to be responsible for cytokine changes cells. In contrast, Klimpel et al 11 found an increased production of the Th-1 cytokine IFN-␥ by spleen cells during observed in patients with cGVHD.
In conclusion, significantly decreased IL-10 production cGVHD. Immunological findings like lymphoid hypoplasia associated with cGVHD were completely suppressed by a and increased median IFN-␥ production was found in patients with cGVHD compared to healthy controls and blocking IFN-␥ antibody. Thus, in addition to Th-2 cytokines, Th-1 proteins might be responsible for the occurpatients without cGVHD. Both cytokines might be involved in the pathogenesis of cGVHD because IL-10 is a potent rence of cGVHD depending on the experimental models used for studying cGVHD.
inhibitor of alloreaction and IFN-␥ production, while IFN-␥ mediates some of the clinical symptoms of cGVHD. Thus, In contrast to murine models, Ig serum levels in humans with cGVHD are decreased compared with healthy longsupplementation of IL-10-deficient patients at risk for cGVHD might prevent or attenuate its course. term survivors, 7 indicating impaired B cell function rather than B cell hyper-reactivity. Since IL-10 is a potent regulator of Ig production in humans, 12 the deficient IL-10 pro
